Literature DB >> 23351335

IgG4-related disease: why high IgG4 and fibrosis?

Takao Koike.   

Abstract

The hallmarks of IgG4-related disease (IgG4-RD) are lymphoplasmacytic tissue infiltration with a predominance of IgG4-positive plasma cells, accompanied by fibrosis, obliterative phlebitis, dacryoadenitis, and elevated levels of IgG4. In a recent issue of Arthritis Research & Therapy, Tsuboi and colleagues demonstrated that regulatory T (Treg) cell-and T helper 2 (Th2) cell-derived cytokines contribute to the pathogenesis of Mikulicz's disease, an activation pathway that appears to be common for IgG4-RD. Additional organ-specific factors may account for the different organ involvement of IgG4-RD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23351335      PMCID: PMC3672717          DOI: 10.1186/ar4122

Source DB:  PubMed          Journal:  Arthritis Res Ther        ISSN: 1478-6354            Impact factor:   5.156


IgG4-related disease (IgG4-RD) is a newly categorized disease entity initially recognized in Japan but increasingly also in other parts of the world [1,2]. Most often the diagnosis is made in patients with autoimmune pancreatitis. Additional presentations include patients with lacrimal and salivary gland involvement, formerly Mikulicz's disease (MD), which was once thought to be a subset of Sjögren's syndrome (SS). The hallmarks of IgG4-RD are lymphoplasmacytic tissue infiltration with a dominance of IgG4-positive plasma cells, accompanied by fibrosis, obliterative phlebitis, dacryoadenitis, and elevated levels of IgG4. The pathogenesis of IgG4-RD is poorly understood; findings consistent with both an autoimmune disorder and an allergic disorder are present [1,2]. IgG4 production is controlled primarily by T helper 2 (Th2) cells [3,4]. Th2 cytokines interleukin-4 (IL-4) and IL-13 enhance the production of IgG4 and IgE. In contrast, IL-10, IL-12, and IL-21 shift the balance between IgG4 and IgE, favoring IgG4. In the Th2 cytokine-driven immune reaction, IgG4 production is induced preferentially by the activation of IL-10 produced by regulatory T (Treg) cells [3]. Thus, selective IgG4 induction is referred to as the combined effect of Th2 and Treg cells. In a recent issue of Arthritis Research & Therapy, Tsuboi and colleagues [5] analyzed the expression of IgG4-specific class switch molecules such as Th2 cytokines (IL-4 and IL-13) and Treg cytokines (IL-10 and TGF-β), IgG4-nonspecific B cell regulatory molecules (CD40, CD154, BAFF, APRIL, and IRF4), and activation-induced cytidine deaminase (AID) in the labial salivary glands (LSGs) and peripheral blood mononuclear cells (PBMCs) from patients with IgG4-RD (MD) and SS. The authors provided evidence that IL-10, TGF-β, and AID were overexpressed in LSGs from IgG4-RD (MD) compared with those in patients with SS, suggesting that Treg cytokines (IL-10 and TGF-β) contribute to IgG4-specifc class switch recombination and fibrosis in patients with IgG4-RD (MD) in combination with the IgG4-unrelated molecule, AID (Figure 1).
Figure 1

Molecular mechanism of IgG4-related disease. AID, activation-induced cytidine deaminase; IL, interleukin; TGF-β, transforming growth factor-beta; Th, T helper; Treg, regulatory T.

Molecular mechanism of IgG4-related disease. AID, activation-induced cytidine deaminase; IL, interleukin; TGF-β, transforming growth factor-beta; Th, T helper; Treg, regulatory T. Very recently, Tanaka and colleagues [6] examined the Th1, Th2, and Treg cytokine expression in LSGs from patients with IgG4-RD and SS. The authors showed that the levels of mRNA for both Th2 and Treg cytokines were significantly higher in LSGs from patients with IgG4-RD (MD) but that the expressions of Th1 and Th2 cytokines were higher in LSGs from patients with SS. The upregulation of Treg cytokines is identical to the findings reported by Tsuboi and colleagues [5], indicating that Treg cells play an important role in the pathogenesis of IgG4-RD (MD). In contrast, Tsuboi and colleagues showed that Th2 cytokines such as IL-4 and IL-13 were not significantly overexpressed in LSGs from patients with IgG4-RD (MD) but were increased if compared with those in healthy subjects. This finding supports the notion that Th2 cytokines such as IL-4 and IL-13 play a common B cell-activating role in both IgG4-RD (MD) and SS. Contrary to Th2 and Treg cytokines, Th1 cytokines were upregulated only in LSGs from patients with SS [6], suggesting that Th1 cells function as key players in the pathogenesis of SS. Consistent with the findings in MD, analyses of the expression of cytokines in inflammatory lesions from patients with IgG4-related sclerosing pancreatitis and cholangitis [7] or tubulointerstitial nephritis [8] showed that tissue mRNA expression of Th2 (IL-4) and Treg cytokines (IL-10 and TGF-β) was substantially higher than in other diseases. Many mononuclear cells expressing IL-4 or IL-10 were identifiable in affected organs by in situ hybridization [7]. Moreover, circulating CD4+CD25+Treg cells were significantly increased in PBMCs from patients with autoimmune pancreatitis [9]. Further examinations should shed light on the molecular mechanisms controlling the activation of this pathway.

Abbreviations

AID: activation-induced cytidine deaminase; APRIL: a proliferation-inducing ligand; BAFF: B cell-activating factor; IgG4-RD: IgG4-related disease; IL: interleukin; IRF4: interferon regulatory factor 4; LSG: labial salivary gland; MD: Mikulicz's disease; PBMC: peripheral blood mononuclear cell; SS: Sjögren's syndrome; TGF-β: transforming growth factor-beta; Th: T helper; Treg: regulatory T.

Competing interests

The author declares that they have no competing interests.
  9 in total

Review 1.  IgG4-related disease.

Authors:  John H Stone; Yoh Zen; Vikram Deshpande
Journal:  N Engl J Med       Date:  2012-02-09       Impact factor: 91.245

2.  An amplification of IL-10 and TGF-beta in patients with IgG4-related tubulointerstitial nephritis.

Authors:  H Nakashima; K Miyake; M Moriyama; A Tanaka; M Watanabe; Y Abe; H Sato; S Nakamura; T Saito
Journal:  Clin Nephrol       Date:  2010-05       Impact factor: 0.975

Review 3.  What is IgG4? A review of the biology of a unique immunoglobulin subtype.

Authors:  Ajay Nirula; Scott M Glaser; Susan L Kalled; Frederick R Taylor; Frederick R Taylora
Journal:  Curr Opin Rheumatol       Date:  2011-01       Impact factor: 5.006

4.  Th2 and regulatory immune reactions contribute to IgG4 production and the initiation of Mikulicz disease.

Authors:  Akihiko Tanaka; Masafumi Moriyama; Hitoshi Nakashima; Katsuhisa Miyake; Jun-Nosuke Hayashida; Takashi Maehara; Shouichi Shinozaki; Yoshiaki Kubo; Seiji Nakamura
Journal:  Arthritis Rheum       Date:  2012-01

Review 5.  Immunoglobulin G4: an odd antibody.

Authors:  R C Aalberse; S O Stapel; J Schuurman; T Rispens
Journal:  Clin Exp Allergy       Date:  2009-02-13       Impact factor: 5.018

6.  Th2 and regulatory immune reactions are increased in immunoglobin G4-related sclerosing pancreatitis and cholangitis.

Authors:  Yoh Zen; Takahiko Fujii; Kenichi Harada; Mitsuhiro Kawano; Kazunori Yamada; Masayuki Takahira; Yasuni Nakanuma
Journal:  Hepatology       Date:  2007-06       Impact factor: 17.425

7.  Circulating naïve and CD4+CD25high regulatory T cells in patients with autoimmune pancreatitis.

Authors:  Hideaki Miyoshi; Kazushige Uchida; Takao Taniguchi; Shujiro Yazumi; Mitsunobu Matsushita; Makoto Takaoka; Kazuichi Okazaki
Journal:  Pancreas       Date:  2008-03       Impact factor: 3.327

8.  Analysis of IgG4 class switch-related molecules in IgG4-related disease.

Authors:  Hiroto Tsuboi; Naomi Matsuo; Mana Iizuka; Sayaka Tsuzuki; Yuya Kondo; Akihiko Tanaka; Masafumi Moriyama; Isao Matsumoto; Seiji Nakamura; Takayuki Sumida
Journal:  Arthritis Res Ther       Date:  2012-07-23       Impact factor: 5.156

Review 9.  A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details.

Authors:  Hisanori Umehara; Kazuichi Okazaki; Yasufumi Masaki; Mitsuhiro Kawano; Motohisa Yamamoto; Takako Saeki; Shoko Matsui; Takayuki Sumida; Tsuneyo Mimori; Yoshiya Tanaka; Kazuo Tsubota; Tadashi Yoshino; Shigeyuki Kawa; Ritsuro Suzuki; Tsutomu Takegami; Naohisa Tomosugi; Nozomu Kurose; Yasuhito Ishigaki; Atsushi Azumi; Masaru Kojima; Shigeo Nakamura; Dai Inoue
Journal:  Mod Rheumatol       Date:  2011-09-01       Impact factor: 3.023

  9 in total
  4 in total

1.  Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations.

Authors:  Zachary S Wallace; Hamid Mattoo; Mollie Carruthers; Vinay S Mahajan; Emanuel Della Torre; Hang Lee; Maria Kulikova; Vikram Deshpande; Shiv Pillai; John H Stone
Journal:  Ann Rheum Dis       Date:  2014-05-09       Impact factor: 19.103

2.  IgG4-related membranous glomerulonephritis and generalized lymphadenopathy without pancreatitis: a case report.

Authors:  Justine Huart; Stéphanie Grosch; Christophe Bovy; Michel Moutschen; Jean-Marie Krzesinski
Journal:  BMC Nephrol       Date:  2017-04-26       Impact factor: 2.388

3.  Activation of Mast-Cell-Derived Chymase in the Lacrimal Glands of Patients with IgG4-Related Ophthalmic Disease.

Authors:  Yasushi Fujita; Denan Jin; Masashi Mimura; Yohei Sato; Shinji Takai; Teruyo Kida
Journal:  Int J Mol Sci       Date:  2022-02-25       Impact factor: 5.923

4.  Extensive Metastatic Cholangiocarcinoma Associated With IgG4-Related Sclerosing Cholangitis Misdiagnosed as Isolated IgG4-Related Sclerosing Cholangitis: A Case Report and Literature Review.

Authors:  Yi-An Zhang; Xi-Zhong Shen; Ji-Min Zhu; Tao-Tao Liu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.